How to Switch Between Peptides: Washout Periods, Bridging, and Transitioning Protocols Safely

For most peptide protocol transitions, the process is straightforward: finish your current cycle (or stop at a natural break point), wait a brief period if needed, and start the new peptide. There is no universal 'washout period' that applies to all peptides because different compounds have different half-lives, different mechanisms, and different receptor dynamics. General guidelines for common transitions: **Switching between recovery peptides** (e.g., BPC-157 to TB-500, or vice versa): no washout needed. These peptides work through different mechanisms and do not compete for the same receptors. Many protocols use them simultaneously (stacking). You can switch immediately or run them in sequence. **Switching between growth hormone secretagogues** (e.g., ipamorelin to GHRP-6, or CJC-1295 to sermorelin): a brief washout of 1-2 weeks is sometimes recommended because these compounds target the same or similar receptors (ghrelin receptor, GHRH receptor). Switching without a washout may mean the new peptide encounters partially desensitized receptors from the previous one. However, many protocols switch directly without washout and report adequate response. **Switching GLP-1 agonists** (e.g., semaglutide to tirzepatide): these are prescription medications with specific titration schedules. Switching between them should be done under medical supervision. The general approach: stop the current GLP-1 at the end of the weekly dosing interval, then start the new one at the lowest dose and re-titrate upward. There is typically no washout needed because the switch IS the transition — you are going from one GLP-1R agonist to another with a similar mechanism. **Switching from TRT to a different testosterone ester**: no washout needed. The body processes all testosterone esters the same way — only the release rate differs. You can switch from cypionate to enanthate on your next injection with no transition issues. **Ending a cycle and starting a new one of the same peptide**: this IS where a washout matters. Growth hormone secretagogues that cause receptor desensitization need a 4-6 week break between cycles to allow receptor recovery. BPC-157 and TB-500 typically have 2-4 week breaks between cycles by convention. Log all protocol changes (new peptide start dates, stop dates, washout periods) in Dosed. The app marks transitions on your timeline so you can correlate response changes with the switch. This content is for educational and research purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

A washout period is a gap between stopping one compound and starting another, allowing the first compound to clear from your system and its effects to dissipate. Whether a washout is necessary depends on the pharmacology of the specific peptides involved. **Washout IS important when**: 1. **Both peptides target the same receptor** and the first one causes desensitization. Switching from one ghrelin receptor agonist to another without a break means the new agonist encounters a partially desensitized receptor — potentially reducing its effectiveness. A 1-4 week washout allows receptor recovery. 2. **The first peptide has a long half-life or depot effect**. CJC-1295 with DAC (drug affinity complex) has a half-life of about 6-8 days. If you switch to a different GHRH analog immediately, both will be active simultaneously for several days, which may not be the intent. Waiting 2-3 half-lives (12-24 days) ensures the first compound has mostly cleared. 3. **You are switching between compounds with potential interactions**. Some peptides affect overlapping pathways. If two compounds both stimulate IGF-1 production, running them simultaneously may produce more stimulation than intended. A washout allows you to see the response to each compound independently. 4. **You need a clean baseline for lab work**. If you are drawing labs to assess the response to a new peptide, any residual effect from the previous one confounds the results. A washout gives clean baseline labs. **Washout is NOT important when**: 1. **The peptides work through completely different mechanisms**. BPC-157 (tissue repair via growth factor signaling) and ipamorelin (GH secretion via ghrelin receptor) have no mechanistic overlap. Switching or even running them simultaneously is standard practice. 2. **You are switching between delivery methods of the same compound**. Switching from subcutaneous testosterone to intramuscular testosterone requires no washout — it is the same hormone, just a different injection route. 3. **The previous peptide has a very short half-life**. Peptides with half-lives under 2 hours (like most short-acting secretagogues) are essentially cleared within 8-12 hours. No formal washout is needed — just start the new protocol the next day. 4. **You are dose-adjusting within the same compound**. Changing from 250 mcg to 500 mcg of the same peptide does not require a washout — it is a dose adjustment, not a compound switch. **The practical approach**: when in doubt, allow a 1-2 week washout between compounds that affect the same system. This costs you nothing except time and provides a clean transition. For compounds targeting different systems, switch immediately with confidence. Dosed tracks the half-life of each logged peptide and can suggest appropriate washout durations based on the specific compounds you are transitioning between.

Sometimes you do not want to stop one compound cold turkey before starting another — you want to BRIDGE by overlapping them for a transition period. Bridging is common in TRT (transitioning between esters), GLP-1 protocols (transitioning between semaglutide and tirzepatide), and multi-compound stacks where you are replacing one component while continuing others. **TRT ester bridging**: when switching from testosterone cypionate (7-8 day half-life) to testosterone enanthate (7 day half-life), no bridging is needed — inject the new ester on the day you would have injected the old one. The pharmacokinetics are so similar that there is no perceptible transition. For switching from a long-acting ester to a short-acting one (e.g., cypionate to propionate), you can start the propionate injections immediately while the cypionate depot is still releasing. Blood levels will be temporarily elevated (from both sources) but will normalize within 1-2 weeks as the cypionate clears. **GLP-1 bridging**: when switching between semaglutide and tirzepatide (both weekly injections), the standard approach is to stop semaglutide at the end of a dosing week and start tirzepatide at the lowest dose the following week. There is a brief overlap (semaglutide has a ~7-day half-life, so it is still partially active when tirzepatide starts), but this is usually well-tolerated. The key: start the new GLP-1 at the LOWEST dose regardless of your previous dose — retitrate to avoid GI side effects. **Stack component replacement**: if you are running a stack (e.g., ipamorelin + CJC-1295 + BPC-157) and want to replace ipamorelin with sermorelin while continuing the other two, simply stop ipamorelin and start sermorelin. Continue CJC-1295 and BPC-157 unchanged. The only component affected by the switch is the one being replaced. **What to document during a transition**: - Date the old compound was last administered - Date the new compound was first administered - Any overlap period and the doses of both compounds during overlap - Subjective response during the transition (did symptoms change? did side effects appear?) - Labs drawn at baseline (before switch), at transition (during), and at steady state (4-6 weeks after) This documentation is essential for understanding how the new protocol is working compared to the old one. Without it, you cannot attribute changes to the switch versus other factors (diet, sleep, stress, training). Dosed marks protocol transitions with timeline annotations, tracks overlapping compounds during bridge periods, and reminds you to draw labs at the appropriate intervals after switching.

A protocol change is a natural experiment — you are changing one variable (the peptide) and observing the effect. To learn from the experiment, you need to control and document the other variables. **Before the switch (baseline, 1-2 weeks before)**: - Draw labs if relevant to the compounds involved - Log 7-14 days of daily symptoms at the current protocol (energy, sleep, mood, recovery, libido, appetite — whatever matters for your protocol) - Note body weight, measurements, and any performance metrics you track - Document the current protocol precisely (compound, dose, frequency, timing, injection site) **During the switch (days 1-14 of new protocol)**: - Log daily symptoms with particular attention to NEW symptoms that were not present before - Note any side effects (injection site reactions, GI issues, headaches, mood changes) - Track whether the transition symptoms (if any) are improving or worsening over the first 2 weeks - Continue the same lifestyle factors (sleep, diet, exercise) as much as possible to isolate the protocol change as the variable **After the switch (weeks 3-8, steady state)**: - Draw follow-up labs at 6-8 weeks post-switch (this is when most peptides reach steady state) - Compare symptom data from before the switch to the steady-state period - Evaluate whether the new protocol is producing the desired response - Adjust dose if needed based on the response and lab data **What NOT to change during a protocol switch**: - Do not simultaneously change your diet, training program, sleep schedule, or other supplements. If you change 3 things at once and feel better, you do not know which change helped. - Do not change the dose of the new compound within the first 2 weeks unless side effects require it. Give the compound time to establish its response before adjusting. - Do not panic about temporary changes during the first week. Transitioning between compounds often produces a brief adjustment period (1-7 days) where symptoms fluctuate before stabilizing. **The data payoff**: after 2-3 protocol transitions documented this way, you have a personal database of how your body responds to different compounds. This data is more valuable than any general protocol recommendation because it is YOUR response. Bring the data to medical appointments to have informed conversations about what works for you specifically. Dosed is built to capture this longitudinal protocol data. Each transition is marked on the timeline, symptoms are tracked daily, and labs are correlated with protocol phases — giving you a clear picture of how each change affected your body.